Please use this identifier to cite or link to this item:
標題: Obatoclax, a Pan-BCL-2 Inhibitor, Targets Cyclin D1 for Degradation to Induce Antiproliferation in Human Colorectal Carcinoma Cells
作者: Or, Chi-Hung R
Chang, Yachu
Lin, Wei-Cheng
Lee, Wee-Chyan
Su, Hong-Lin
Cheung, Muk-Wing
Huang, Chang-Po
Ho, Cheesang
Chang, Chia-Che
關鍵字: BH3 (BCL-2 homology 3) mimetics;G1-phase arrest;antiproliferation;colorectal cancer;cyclin D1;obatoclax;proteasomal degradation;Carcinoma;Cell Proliferation;Colorectal Neoplasms;Cyclin D1;Down-Regulation;G1 Phase Cell Cycle Checkpoints;HCT116 Cells;HT29 Cells;Humans;Proteolysis;Proto-Oncogene Proteins c-bcl-2;Pyrroles
Project: International journal of molecular sciences, Volume 18, Issue 1
Colorectal cancer is the third most common cancer worldwide. Aberrant overexpression of antiapoptotic BCL-2 (B-cell lymphoma 2) family proteins is closely linked to tumorigenesis and poor prognosis in colorectal cancer. Obatoclax is an inhibitor targeting all antiapoptotic BCL-2 proteins. A previous study has described the antiproliferative action of obatoclax in one human colorectal cancer cell line without elucidating the underlying mechanisms. We herein reported that, in a panel of human colorectal cancer cell lines, obatoclax inhibits cell proliferation, suppresses clonogenicity, and induces G₁-phase cell cycle arrest, along with cyclin D1 downregulation. Notably, ectopic cyclin D1 overexpression abrogated clonogenicity suppression but also G₁-phase arrest elicited by obatoclax. Mechanistically, pre-treatment with the proteasome inhibitor MG-132 restored cyclin D1 levels in all obatoclax-treated cell lines. Cycloheximide chase analyses further revealed an evident reduction in the half-life of cyclin D1 protein by obatoclax, confirming that obatoclax downregulates cyclin D1 through induction of cyclin D1 proteasomal degradation. Lastly, threonine 286 phosphorylation of cyclin D1, which is essential for initiating cyclin D1 proteasomal degradation, was induced by obatoclax in one cell line but not others. Collectively, we reveal a novel anticancer mechanism of obatoclax by validating that obatoclax targets cyclin D1 for proteasomal degradation to downregulate cyclin D1 for inducing antiproliferation.
DOI: 10.3390/ijms18010044
Appears in Collections:生物醫學研究所

Files in This Item:
File Description SizeFormat Existing users please Login
ijms-18-00044.pdf期刊論文2.96 MBAdobe PDFThis file is only available in the university internal network    Request a copy
Show full item record

Google ScholarTM




Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.